Cefditoren
Based on 1 publication(s) in Google Scholar
Cefditoren is a broad-spectrum oral active cephalosporin that acts as a penicillin-binding protein (PBP) inhibitor. Cefditoren binds to specific PBPs in Gram-positive and Gram-negative bacteria, thereby inhibiting cell wall synthesis. Cefditoren also reduces serum levels of the inflammatory biomarkers IL-6 and KL-6. Cefditoren can be used in research related to acute exacerbation of chronic bronchitis, pharyngitis-tonsillitis, uncomplicated skin and skin structure infections, respiratory tract infections, acute pyelonephritis, and enterococcal endocarditis.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 98.14%
- CAS 番号: 104145-95-1
- 分子式: C19H18N6O5S3
- 分子量:506.58
-
保管条件:
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
-
Antibacterial Compound Library
HY-L049
-
Orally Active Compound Library
HY-L061
-
Antibiotics Library
HY-L067
-
Angiogenesis-Related Compound Library
HY-L088
-
Antidepressant Compound Library
HY-L108
-
Anti-Prostate Cancer Compound Library
HY-L124
-
Pain-Related Compound Library
HY-L139
-
Autoimmune Disease Compound Library
HY-L156
-
Highly Selective Inhibitors Library
HY-L158
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
-
Anti-Infection Compound Library
HY-L002
-
Immunology/Inflammation Compound Library
HY-L007
MedChemExpress（MCE）の使用を引用している文献 Cefditoren
MoreAntibiotic アイソフォーム固有の製品をすべて表示
More
生物活性
Cefditoren potently inhibits clinical isolates of S. pneumoniae (MIC90 0.5 μg/mL), β-haemolytic streptococci (MIC90 0.06 μg/mL), viridans group streptococci (MIC90 1 μg/mL), β-lactamase-negative H. influenzae (MIC90 0.03 μg/mL), β-lactamase-positive H. influenzae (MIC90 0.016 μg/mL), β-lactamase-negative M. catarrhalis (MIC90 0.06 μg/mL), and β-lactamase-positive M. catarrhalis (MIC90 0.5 μg/mL), with 100% susceptibility of all these groups at ≤1 μg/mL except viridans group streptococci (90.3% susceptible at ≤1 μg/mL)[1].
Cefditoren inhibits penicillin-susceptible S. pneumoniae (MIC90 0.015-0.03 μg/mL), penicillin-intermediate S. pneumoniae (MIC90 0.5 μg/mL), and penicillin-resistant S. pneumoniae (MIC90 0.5-2 μg/mL), with increasing MIC values corresponding to increased penicillin resistance[1].
Cefditoren potently inhibits C. perfringens (MIC90 1 μg/mL) and B. (P.) melaninogenicus (MIC90 4 μg/mL)[1].
Cefditoren exhibits potent in vitro activity against S. pneumoniae, H. influenzae, non-ESBL-producing K. pneumoniae, and non-ESBL-producing E. coli, with the lowest MIC90 among tested cephalosporins for S. pneumoniae, but is inactive against ESBL- and carbapenemase-producing strains[3].
Cefditoren is stable against most common plasmidic beta-lactamases produced by H. influenzae and M. catarrhalis, retains activity against BLNAR H. influenzae, but is susceptible to hydrolysis by extended-spectrum beta-lactamases[3].
Cefditoren exhibits potent in vitro activity against multi-drug resistant S. pneumoniae, beta-lactamase-producing H. influenzae and M. catarrhalis, and S. pyogenes, with only 7% of PEN-R S. pneumoniae strains showing resistance[3].
Cefditoren exhibits potent in vitro activity against MSSA and 100% in vitro activity against S. pyogenes strains associated with SSTIs[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
化学情報
-
CAS 番号 104145-95-1
-
性状 Solid
-
分子量 506.58
-
分子式 C19H18N6O5S3
-
Color Light yellow to yellow
-
SMILES
OC(C1=C(/C=C\C2=C(N=CS2)C)CS[C@@]([C@@H]3NC(/C(C4=CSC(N)=N4)=N\OC)=O)([H])N1C3=O)=O
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (1)
-
Journal Impact Factor
-
Most Recent
溶剤 & 溶解度
DMSO : 50 mg/mL (98.70 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1.25 mg/mL (2.47 mM); Clear solution
This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 1.25 mg/mL (2.47 mM); Clear solution
This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
純度とドキュメンテーション
-
データシート (281 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Jones RN, et al. Cefditoren in vitro activity and spectrum: a review of international studies using reference methods. Diagn Microbiol Infect Dis. 2001 Sep-Oct;41(1-2):1-14. [Content Brief]
[2]. Balbisi EA, et al. Cefditoren, a new aminothiazolyl cephalosporin. Pharmacotherapy. 2002;22(10):1278-1293. [Content Brief]
[3]. Giuliano S, et al. Cefditoren: a clinical overview. New Microbiol. 2023;46(1):9-17. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.9740 mL | 9.8701 mL | 19.7402 mL | 49.3505 mL |
| 5 mM | 0.3948 mL | 1.9740 mL | 3.9480 mL | 9.8701 mL | |
| 10 mM | 0.1974 mL | 0.9870 mL | 1.9740 mL | 4.9351 mL | |
| 15 mM | 0.1316 mL | 0.6580 mL | 1.3160 mL | 3.2900 mL | |
| 20 mM | 0.0987 mL | 0.4935 mL | 0.9870 mL | 2.4675 mL | |
| 25 mM | 0.0790 mL | 0.3948 mL | 0.7896 mL | 1.9740 mL | |
| 30 mM | 0.0658 mL | 0.3290 mL | 0.6580 mL | 1.6450 mL | |
| 40 mM | 0.0494 mL | 0.2468 mL | 0.4935 mL | 1.2338 mL | |
| 50 mM | 0.0395 mL | 0.1974 mL | 0.3948 mL | 0.9870 mL | |
| 60 mM | 0.0329 mL | 0.1645 mL | 0.3290 mL | 0.8225 mL | |
| 80 mM | 0.0247 mL | 0.1234 mL | 0.2468 mL | 0.6169 mL |
Cefditoren 関連分類
HY-159688 関連分類
Powered by Bioz
- Cefditoren
- 104145-95-1
- Antibiotic
- Bacterial
- Penicillin-binding protein (PBP)
- Interleukin Related
- Moraxella catarrhalis
- Gram-negative bacteria
- Escherichia coli
- Haemophilus influenzae
- Streptococcus pyogenes
- Klebsiella pneumoniae
- penicillin-binding protein
- Streptococcus pneumoniae
- Gram-positive bacteria
- Staphylococcus aureus
- Inhibitor
- inhibitor
- inhibit